A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

NCT05620940 | Recruiting Phase 1 DMC

• 1 other identifier: IVL3004-001
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

Conditions

Opioid Dependence; Alcohol Dependence; Multiple Sclerosis

Outcome Measures

Primary Outcomes (5)

• AUC0-240

  Area under the concentration-time curve from time zero to 240hrs

  Pre-dose, up to Day 57

• Cmax

  The maximal observed concentration

  Pre-dose, up to Day 57

• AUC240-672

  Area under the concentration-time curve from time 240 to 672hrs

  Pre-dose, up to Day 57

• AUC0-672

  Area under the concentration-time curve from time zero to 672hrs

  Pre-dose, up to Day 57

• AUC0-inf

  Area under the concentration-time curve from time zero to infinity

  Pre-dose, up to Day 57

Study Arms (4)

Part A Group 1 (Vivitrol Injection)

ACTIVE COMPARATOR

Vivitrol, Single Dose, IM injection

Drug: Vivitrol Injectable Product

Part A Group 2 (IVL3004 A mg)

EXPERIMENTAL

IM, Single Dose

Drug: IVL3004

Part A Group 3 IVL3004 B mg)

EXPERIMENTAL

IM, Single Dose

Drug: IVL3004

Part B Group 1 (IVL4002 Cmg)

EXPERIMENTAL

SC, Single Dose

Drug: IVL4002

Interventions

Vivitrol Injectable Product DRUG

Naltrexone Long-Acting Injection

Part A Group 1 (Vivitrol Injection)

IVL3004 DRUG

Naltrexone Long-Acting Injection

Part A Group 2 (IVL3004 A mg); Part A Group 3 IVL3004 B mg)

IVL4002 DRUG

Naltrexone Long-Acting Injection

Part B Group 1 (IVL4002 Cmg)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult male, ≥18 and ≤55 years of age, non-smokers or occasional smokers (defined as smoking less than 10 cigarettes or nicotine equivalent per week, and willing to abstain from smoking during confinement at the clinical site).
• BMI ≥18.0 and ≤32.0 kg/m2 and body weight ≥55.0 kg.
• Healthy as defined by:
• The absence of clinically significant illness, infection, or medical/surgical procedure within 4 weeks prior to dosing or planned inpatient surgery (including dental surgery) or hospitalization during the study period.
• The absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological (including autoimmune), psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
• Subjects who are not vasectomized for at least 3 months prior to dosing, and who are sexually active with a female partner of childbearing potential must be willing to use one of the following acceptable contraceptive methods from dosing and for 90 days after dosing:
• a. Simultaneous use of a male condom and, for the female partner, hormonal contraceptives used for at least 4 weeks or intrauterine device placed for at least 4 weeks prior to dosing.
• Subjects who have had a vasectomy must be willing to use a condom until study exit.
• Subjects who practice abstinence from sexual intercourse as a usual and preferred lifestyle.
• Subjects must be willing not to donate sperm for 90 days after dosing.
• Willing to undergo SC abdominal injection or IM ventral gluteal injection to allow for investigational drug administration.
• Willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any protocol- specific study procedures.

You may not qualify if:

• Any clinically significant abnormal finding at physical examination at screening or Day -1.
• Clinically significant abnormal laboratory test results at screening or Day -1, or positive serology test results for human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus at screening.
• Is prone to skin rashes, irritation, or has a skin condition such as recurrent eczema that is likely to impact the injection site area or demonstrates any abnormal skin tissue in the proposed injection area, as determined by the Investigator.
• Any history of malignancy or neoplastic disease.
• History of significant allergic reactions (e.g., drug reaction, anaphylactic reaction, hypersensitivity, angioedema) to any drug, or to any excipient present in the formulations.
• ALT, AST, or total bilirubin \>1.5x upper limit of normal (ULN) at screening or Day -1.
• Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2 as calculated by the 2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) equation at screening or Day -1.
• Clinically significant ECG abnormalities (QTc \>450 ms or PR interval \>220 ms) or vital sign abnormalities (systolic blood pressure \<90 or \>140 mmHg, diastolic blood pressure \<40 or \>90 mmHg, or heart rate \<40 or \>100 bpm) at screening or Day -1.
• History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 14 units of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of spirit 40%), or positive alcohol test at screening or Day -1.
• History of drug abuse within 1 year prior to screening or positive test for drugs of abuse (e.g., phencyclidine, opiates, benzodiazepines, barbiturates, amphetamines, methamphetamines, cocaine, and tetrahydrocannabinol) at screening or Day -1.
• Presence of any underlying physical or psychological (e.g., depression) medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the protocol or complete the study per protocol. Mild depression and anxiety that has been resolved at least 6 months prior to screening is accepted.
• Use of medications for the timeframes specified below, with the exception of hormonal contraceptives and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety:
• Depot injection or implant within 3 months prior to dosing;
• Strong CYP inhibitors or inducers within 30 days prior to dosing;
• Prescription medications within 14 days prior to dosing;

Sponsors & Collaborators

• Inventage Lab., Inc.: lead

Study Sites (1)

Nucleus Network

Herston, Queensland, 4006, Australia

RECRUITING

MeSH Terms

Conditions

Opioid-Related Disorders; Alcoholism; Multiple Sclerosis

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Alcohol-Related Disorders; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

HyeRyeon Kim

CONTACT

82-31-608-0514; hr.kim@inventagelab.com

Heesun Kim

CONTACT

82-31-608-0514; flower@inventagelab.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 10, 2022
• First Posted: November 17, 2022
• Study Start: September 11, 2024
• Primary Completion: December 30, 2025
• Study Completion: December 30, 2025
• Last Updated: September 15, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)